DIO 901

Drug Profile

DIO 901

Alternative Names: DIO-901; Very Low Dose Glucagon; VLDG

Latest Information Update: 30 Dec 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DiObex
  • Class Antihyperglycaemics; Hormones; Peptides
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypoglycaemia

Most Recent Events

  • 05 Feb 2009 Clinical development is ongoing in USA
  • 18 Mar 2008 DiObex and Camurus sign a license agreement to develop DIO 901 in an ER formulation using FluidCrystal® delivery technology for Hypoglycaemia
  • 29 Jun 2007 Data presented at the 67th Scientific Sessions of the American Diabetes Association (ADA-2007) added to the Metabolic disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top